"Promising Weight Loss Drugs Show Potential Cardiorenal Benefits in Kidney Disease Patients"
New weight loss drugs, such as glycogen-like peptide-1 receptor antagonists (GLP-1 RAs) and sodium glucose contransporter-2 (SGLT2) inhibitors, may have cardiorenal benefits for patients with chronic kidney disease (CKD), according to a nephrology specialist. These drugs have shown potential cardioprotective effects and metabolic improvements in patients with CKD, who often have obesity and metabolic syndrome. However, there is limited safety data for these drugs in CKD patients, and further research is needed to determine their efficacy and potential risks for advanced and end-stage CKD.